- Home
- TNXP vs AVIR Comparison
TNXP vs AVIR Comparison
Compare TNXP & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- AVIR
- Stock Information
- Founded
- TNXP 2007
- AVIR 2012
- Country
- TNXP United States
- AVIR United States
- Employees
- TNXP N/A
- AVIR N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- TNXP Health Care
- AVIR Health Care
- Exchange
- TNXP Nasdaq
- AVIR Nasdaq
- Market Cap
- TNXP 335.6M
- AVIR 290.4M
- IPO Year
- TNXP N/A
- AVIR 2020
- Fundamental
- Price
- TNXP $28.35
- AVIR $3.00
- Analyst Decision
- TNXP Buy
- AVIR Hold
- Analyst Count
- TNXP 1
- AVIR 1
- Target Price
- TNXP $70.00
- AVIR $6.00
- AVG Volume (30 Days)
- TNXP 1.2M
- AVIR 217.7K
- Earning Date
- TNXP 11-11-2025
- AVIR 11-06-2025
- Dividend Yield
- TNXP N/A
- AVIR N/A
- EPS Growth
- TNXP N/A
- AVIR N/A
- EPS
- TNXP N/A
- AVIR N/A
- Revenue
- TNXP $9,831,000.00
- AVIR N/A
- Revenue This Year
- TNXP $14.79
- AVIR N/A
- Revenue Next Year
- TNXP $933.49
- AVIR N/A
- P/E Ratio
- TNXP N/A
- AVIR N/A
- Revenue Growth
- TNXP N/A
- AVIR N/A
- 52 Week Low
- TNXP $6.76
- AVIR $2.46
- 52 Week High
- TNXP $130.00
- AVIR $4.15
- Technical
- Relative Strength Index (RSI)
- TNXP 41.38
- AVIR 35.03
- Support Level
- TNXP $26.89
- AVIR $2.84
- Resistance Level
- TNXP $29.19
- AVIR $3.33
- Average True Range (ATR)
- TNXP 2.18
- AVIR 0.14
- MACD
- TNXP 0.39
- AVIR -0.04
- Stochastic Oscillator
- TNXP 56.46
- AVIR 22.63
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).